

Brian J Ward

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8737463/brian-j-ward-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

88

papers

2,312

citations

28

h-index

45

g-index

93

ext. papers

2,930

ext. citations

7.3

avg, IF

4.86

L-index

#	Paper	IF	Citations
88	Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.. <i>Cellular and Molecular Immunology</i> , 2022 ,	15.4	5
87	Relationship between lay and expert perceptions of COVID-19 vaccine development timelines in Canada and USA.. <i>PLoS ONE</i> , 2022 , 17, e0262740	3.7	
86	Cryptococcal Meningitis Reported With Fingolimod Treatment: Case Series.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	3
85	Elimination of receptor binding by influenza hemagglutinin improves vaccine-induced immunity.. <i>Npj Vaccines</i> , 2022 , 7, 42	9.5	1
84	Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.. <i>New England Journal of Medicine</i> , 2022 ,	59.2	7
83	Lack of effects on female fertility or pre- and postnatal development of offspring in rats after exposure to AS03-adjuvanted recombinant plant-derived virus-like particle vaccine candidate for COVID-19. <i>Reproductive Toxicology</i> , 2021 , 107, 69-80	3.4	1
82	Is Conflict of interest Ta Misnomer? Managing interests in immunization research and evaluation. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 1-6	4.4	1
81	Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49 years of age. <i>Vaccine</i> , 2021 , 39, 1528-1533	4.1	12
80	Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2021 , 39, 3053-3066	4.1	28
79	Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. <i>Nature Medicine</i> , 2021 , 27, 1071-1078	50.5	66
78	Barriers and facilitators to influenza and pneumococcal vaccine hesitancy in rheumatoid arthritis: a qualitative study. <i>Rheumatology</i> , 2021 , 60, 5257-5270	3.9	2
77	A multimodal intervention increases influenza vaccine uptake in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021 , 40, 575-579	3.9	1
76	Relative effectiveness of influenza vaccines in elderly persons in the United States, 2012/2013-2017/2018 seasons. <i>Npj Vaccines</i> , 2021 , 6, 108	9.5	2
75	Therapeutic activity of a Salmonella-vectored Schistosoma mansoni vaccine in a mouse model of chronic infection. <i>Vaccine</i> , 2021 , 39, 5580-5588	4.1	2
74	Suboptimal Immunization Coverage among Canadian Rheumatology Patients in Routine Clinical Care. <i>Journal of Rheumatology</i> , 2020 , 47, 770-778	4.1	13
73	Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial. <i>Lancet Rheumatology</i> , 2020 , 2, e14-e23	14.2	9
72	Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials. <i>Lancet, The</i> , 2020 , 396, 1491-1503	40	62

71	Expert Forecasts of COVID-19 Vaccine Development Timelines. <i>Journal of General Internal Medicine</i> , 2020 , 35, 3753-3755	4	8
70	Exposure to lead and vaccine-specific IgG titers in South African children participating in the Venda Health Examination of Mothers, Babies and their Environment (VHEMBE): A longitudinal study. <i>Environmental Research</i> , 2020 , 180, 108794	7.9	3
69	Needle-free delivery of influenza vaccine using the Med-Jet [®] H4 is efficient and elicits the same humoral and cellular responses as standard IM injection: A randomized trial. <i>Vaccine</i> , 2019 , 37, 1332-1339 ¹	4.1	4
68	Vaccination against by Use of an Attenuated Serovar Typhimurium Vector (YS1646) Protects Mice from Lethal Challenge. <i>Infection and Immunity</i> , 2019 , 87,	3.7	2
67	Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages. <i>Npj Vaccines</i> , 2019 , 4, 17	9.5	15
66	Assessment of population immunity to measles in Ontario, Canada: a Canadian Immunization Research Network (CIRN) study. <i>Human Vaccines and Immunotherapeutics</i> , 2019 , 15, 2856-2864	4.4	4
65	Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and 50 years old adults. <i>PLoS ONE</i> , 2019 , 14, e0216533	3.7	56
64	Comparative Immunogenicity of the 2014-2015 Northern Hemisphere Trivalent IIV and LAIV against Influenza A Viruses in Children. <i>Vaccines</i> , 2019 , 7,	5.3	7
63	Prime-pull vaccination with a plant-derived virus-like particle influenza vaccine elicits a broad immune response and protects aged mice from death and frailty after challenge. <i>Immunity and Ageing</i> , 2019 , 16, 27	9.7	12
62	Vaccination against the digestive enzyme Cathepsin B using a YS1646 Salmonella enterica [®] Typhimurium vector provides almost complete protection against Schistosoma mansoni challenge in a mouse model. <i>PLoS Neglected Tropical Diseases</i> , 2019 , 13, e0007490	4.8	9
61	A plant-derived VLP influenza vaccine elicits a balanced immune response even in very old mice with co-morbidities. <i>PLoS ONE</i> , 2019 , 14, e0210009	3.7	16
60	Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial. <i>Npj Vaccines</i> , 2018 , 3, 3	9.5	33
59	The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?. <i>Human Vaccines and Immunotherapeutics</i> , 2018 , 14, 647-656	4.4	40
58	Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment. <i>Current Medical Research and Opinion</i> , 2018 , 34, 1419-1430	2.5	13
57	Morphological characterization of a plant-made virus-like particle vaccine bearing influenza virus hemagglutinins by electron microscopy. <i>Vaccine</i> , 2018 , 36, 2147-2154	4.1	25
56	Characterization of the innate stimulatory capacity of plant-derived virus-like particles bearing influenza hemagglutinin. <i>Vaccine</i> , 2018 , 36, 8028-8038	4.1	8
55	A novel serological assay for influenza based on DiD fluorescence dequenching that is free from observer bias and potentially automatable - A proof of concept study. <i>Vaccine</i> , 2018 , 36, 4485-4493	4.1	2
54	Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro. <i>Vaccine</i> , 2017 , 35, 2592-2599	4.1	17

53	A Single Intramuscular Dose of a Plant-Made Virus-Like Particle Vaccine Elicits a Balanced Humoral and Cellular Response and Protects Young and Aged Mice from Influenza H1N1 Virus Challenge despite a Modest/Absent Humoral Response. <i>Vaccine Journal</i> , 2017 , 24,		16
52	Plant-made virus-like particles bearing influenza hemagglutinin (HA) recapitulate early interactions of native influenza virions with human monocytes/macrophages. <i>Vaccine</i> , 2017 , 35, 4629-4636	4.1	15
51	Single radial haemolysis compared to haemagglutinin inhibition and microneutralization as a correlate of protection against influenza A H3N2 in children and adolescents. <i>Influenza and Other Respiratory Viruses</i> , 2017 , 11, 283-288	5.6	15
50	A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults. <i>New England Journal of Medicine</i> , 2017 , 377, 2349-2362	59.2	41
49	STAT6 inhibitory peptide given during RSV infection of neonatal mice reduces exacerbated airway responses upon adult reinfection. <i>Journal of Leukocyte Biology</i> , 2017 , 101, 519-529	6.5	12
48	Serum Carbonic Anhydrase 1 is a Biomarker for Diagnosis of Human Infection. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017 , 96, 842-849	3.2	4
47	Low hemagglutinin antigen dose influenza vaccines adjuvanted with AS03 alter the long-term immune responses in BALB/c mice. <i>Human Vaccines and Immunotherapeutics</i> , 2017 , 13, 561-571	4.4	4
46	A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. <i>Clinical Immunology</i> , 2016 , 168, 72-87	9	92
45	Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice. <i>Vaccine</i> , 2016 , 34, 1444-51	4.1	16
44	Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories. <i>Vaccine Journal</i> , 2016 , 23, 236-42		42
43	Identification of Candidate Serum Biomarkers for Schistosoma mansoni Infected Mice Using Multiple Proteomic Platforms. <i>PLoS ONE</i> , 2016 , 11, e0154465	3.7	6
42	Dermatoses among returned Canadian travellers and immigrants: surveillance report based on CanTravNet data, 2009-2012. <i>CMAJ Open</i> , 2015 , 3, E119-26	2.5	12
41	A family cluster of Chagas disease detected through selective screening of blood donors: A case report and brief review. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2015 , 26, 157-61	2.6	6
40	AS03-Adjuvanted, Very-Low-Dose Influenza Vaccines Induce Distinctive Immune Responses Compared to Unadjuvanted High-Dose Vaccines in BALB/c Mice. <i>Frontiers in Immunology</i> , 2015 , 6, 207	8.4	17
39	The Effect of Deworming on Growth in One-Year-Old Children Living in a Soil-Transmitted Helminth-Endemic Area of Peru: A Randomized Controlled Trial. <i>PLoS Neglected Tropical Diseases</i> , 2015 , 9, e0004020	4.8	20
38	Generation and characterization of a trackable plant-made influenza H5 virus-like particle (VLP) containing enhanced green fluorescent protein (eGFP). <i>FASEB Journal</i> , 2015 , 29, 3817-27	0.9	10
37	Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children. <i>PLoS ONE</i> , 2015 , 10, e0131531	3.7	56
36	Immunologic characterization of a novel inactivated nasal mumps virus vaccine adjuvanted with Protollin. <i>Vaccine</i> , 2014 , 32, 238-45	4.1	3

35	Inhibition of STAT6 during vaccination with formalin-inactivated RSV prevents induction of Th2-cell-biased airway disease. <i>European Journal of Immunology</i> , 2014 , 44, 2349-59	6.1	6
34	Discovery and characterization of potential prognostic biomarkers for dengue hemorrhagic fever. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014 , 91, 1218-26	3.2	8
33	Influenza virus-like particle vaccines made in <i>Nicotiana benthamiana</i> elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. <i>Clinical Immunology</i> , 2014 , 154, 164-77	9	72
32	Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines. <i>Vaccine</i> , 2014 , 32, 6098-106	4.1	70
31	Seroprevalence of parasitic zoonoses and their relationship with social factors among the Canadian Inuit in Arctic regions. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014 , 78, 404-10	2.9	28
30	Increased emergency room visits or hospital admissions in females after 12-month MMR vaccination, but no difference after vaccinations given at a younger age. <i>Vaccine</i> , 2014 , 32, 1153-9	4.1	4
29	Apolipoprotein A-I truncations in Chagas disease are caused by cruzipain, the major cysteine protease of <i>Trypanosoma cruzi</i> . <i>American Journal of Pathology</i> , 2014 , 184, 976-984	5.8	9
28	Development of a rapid serological assay for the diagnosis of strongyloidiasis using a novel diffraction-based biosensor technology. <i>PLoS Neglected Tropical Diseases</i> , 2014 , 8, e3002	4.8	28
27	Travel-acquired infections and illnesses in Canadians: surveillance report from CanTravNet surveillance data, 2009-2011. <i>Open Medicine</i> , 2014 , 8, e20-32		28
26	In vitro inhibition of mumps virus by retinoids. <i>Virology Journal</i> , 2013 , 10, 337	6.1	12
25	Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine. <i>Vaccine Journal</i> , 2013 , 20, 459-67		14
24	Zoonotic infections in native communities of James Bay, Canada. <i>Vector-Borne and Zoonotic Diseases</i> , 2012 , 12, 473-81	2.4	19
23	Seroprevalence of 10 zoonotic infections in 2 Canadian Cree communities. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011 , 70, 191-9	2.9	20
22	RIG-I is required for the inhibition of measles virus by retinoids. <i>PLoS ONE</i> , 2011 , 6, e22323	3.7	24
21	Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children. <i>Pediatric Infectious Disease Journal</i> , 2011 , 30, 402-7	3.4	22
20	Humoral and cell-mediated immunity to pandemic H1N1 influenza in a Canadian cohort one year post-pandemic: implications for vaccination. <i>PLoS ONE</i> , 2011 , 6, e28063	3.7	34
19	Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. <i>PLoS ONE</i> , 2010 , 5, e15559	3.7	200
18	Retinoids inhibit measles virus through a type I IFN-dependent bystander effect. <i>FASEB Journal</i> , 2009 , 23, 3203-12	0.9	47

17	TLR4 and MyD88 control protection and pulmonary granulocytic recruitment in a murine intranasal RSV immunization and challenge model. <i>Vaccine</i> , 2009 , 27, 421-30	4.1	30
16	Influenza virus-like particles produced by transient expression in <i>Nicotiana benthamiana</i> induce a protective immune response against a lethal viral challenge in mice. <i>Plant Biotechnology Journal</i> , 2008 , 6, 930-40	11.6	198
15	Retinoids inhibit measles virus in vitro via nuclear retinoid receptor signaling pathways. <i>Antiviral Research</i> , 2008 , 80, 45-53	10.8	20
14	Disease manifestations of canine distemper virus infection in ferrets are modulated by vitamin A status. <i>Journal of Nutrition</i> , 2007 , 137, 1916-22	4.1	20
13	C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine. <i>Vaccine</i> , 2007 , 25, 3228-32	4.1	20
12	Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology. <i>Vaccine</i> , 2007 , 25, 5378-89	4.1	19
11	Seroprevalence of zoonoses in a Cree community (Canada). <i>Diagnostic Microbiology and Infectious Disease</i> , 2007 , 59, 283-6	2.9	32
10	Travel and sexually transmitted infections. <i>Journal of Travel Medicine</i> , 2006 , 13, 300-17	12.9	56
9	A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice. <i>Vaccine</i> , 2005 , 23, 1374-83	4.1	41
8	Ineffectiveness of the current strategy to prevent hepatitis A in travelers. <i>Journal of Travel Medicine</i> , 2002 , 9, 10-6	12.9	35
7	No evidence for short or long term morbidity after increased titer measles vaccination in Sudan. <i>Pediatric Infectious Disease Journal</i> , 2002 , 21, 112-9	3.4	12
6	Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. <i>Clinical Infectious Diseases</i> , 2001 , 33, 1847-51	11.6	144
5	Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. <i>Vaccine</i> , 2000 , 18, 1393-401	4.1	44
4	Retinol (vitamin A) supplements in the elderly. <i>Drugs and Aging</i> , 1996 , 9, 48-59	4.7	4
3	Vitamin A status in HIV infection. <i>Nutrition Research</i> , 1993 , 13, 157-166	4	18
2	Cytokine production in vitro and the lymphoproliferative defect of natural measles virus infection. <i>Clinical Immunology and Immunopathology</i> , 1991 , 61, 236-48		66
1	Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants		32